Over 900 biotech medicines in development in USA, targeting more than 100 diseases

18 September 2011

The USA’s biopharmaceutical research companies have 901 biotechnology medicines and vaccines in development to target more than 100 debilitating and life-threatening diseases, such as cancer, arthritis and diabetes, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

The medicines in development - all in either clinical trials or under Food and Drug Administration review - include 353 for cancer and related conditions, 187 for infectious diseases, 69 for autoimmune diseases and 59 for cardiovascular diseases.

There are also 44 treatments for neurologic disorders, 40 for respiratory conditions, 39 for HIV infection, 32 for blood disorders, 28 for skin disorders, 27 for digestive conditions, 24 for diabetes and related conditions, 22 for musculoskeletal disorders, 20 for eye conditions, 19 for genetic disorders, 18 for transplantation and five for growth disorders, notes the report , the full text and tables detailing each product of which is available on the trade group’s web site ( www.phrma.org).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology